The participant demographic (n = 1844). by Mahmoud A. Alomari (14780446)

“…</p><p>Conclusions</p><p>Changes in the SH during COVID-19 have been reported in about 50% of participants who smoke tobacco, with a more reported decrease than increase in use. …”

FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

“…When tumors reached an average of 150 mm³, mice were randomized to receive vehicle (ORA-Plus, 50 μL, n = 7) or FTY720 (10 mg/kg body weight/day in ORA-Plus, 50 μL, n = 7) by oral gavage for 16 days. …”

Capsaicin, pyridoxine, vincristine sulfate and ionomycin significantly decreased axon length ratio but only pyridoxine had no impact on neurotoxicity. by Fei San Lee (17282886)

“…At a lower dose, 1 nM Vcr caused slow axonal dieback in female rat DRGs but did not impact male rat DRGs. …”

Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability by Bárbara Arévalo (4053358)

Subjects:

Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability by Bárbara Arévalo (4053358)

Subjects:

Prevalence of smoking during COVID19 (n = 1844). by Mahmoud A. Alomari (14780446)

“…</p><p>Conclusions</p><p>Changes in the SH during COVID-19 have been reported in about 50% of participants who smoke tobacco, with a more reported decrease than increase in use. …”

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…<p>(a) Left: noise-evoked activity rates at different noise intensities for chronically tracked PPys cells in baseline and repeated stress conditions (<i>N</i> = 5 mice, <i>n</i> = 285 neurons, mean ± SE). …”

RAC1 inhibition results in a decrease in oxidative phosphorylation. by Shruthi Sriramkumar (12705564)

Comparison of mean differences in temperature decreases. by Hans-Jörg Gillmann (8460585)

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

N2142A mutation could reduce mortality rate and severity of symptoms by decreasing viral loads in limb muscle and spinal cord. by Xue Li (285380)

Running decreased hippocampal amyloid burden. by Kaja Falkenhain (9317016)

Ellagic acid decreases mitochondrial damages. by Ahmad Salimi (10204515)

Relative expression of (A) miR-214 and (B) the <i>ATF4</i> target gene after transfection with 40 nM of miR-214 mimics or a negative mimics control for 24 h, followed by treatment... by Tipparat Penglong (164413)

Loss of Prox1a decreases PR production at 120 hours post-ablation. by Kellie Veen (17343374)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”